A citation-based method for searching scientific literature

Angel W Liu, Connie Liang, Chung-Shien Lee. J Oncol Pharm Pract 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines.
Yuichiro Ohshima, Ichiro Yajima, Kozue Takeda, Machiko Iida, Mayuko Kumasaka, Yoshinari Matsumoto, Masashi Kato. PLoS One 2010
36
100

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
171
100

A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Niho, Rakhee Chauhan, Phillip P Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki,[...]. Nat Commun 2018
52
100


Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.
Rebecca L Margraf, David K Crockett, Patti M F Krautscheid, Ryan Seamons, Fernanda R O Calderon, Carl T Wittwer, Rong Mao. Hum Mutat 2009
98
100

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
76
100

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Takuo Hayashi, Igor Odintsov, Roger S Smith, Kota Ishizawa, Allan J W Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic,[...]. Dis Model Mech 2020
6
100

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.
Gang G Li, Romel Somwar, James Joseph, Roger S Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, Anni Schairer, Eric Martin, Gregory J Riely,[...]. Clin Cancer Res 2017
50
100


Catalog of 5' fusion partners in RET+ NSCLC Circa 2020.
Sai-Hong Ignatius Ou, Viola W Zhu. JTO Clin Res Rep 2020
5
100

KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.
Oscar P J van Linden, Albert J Kooistra, Rob Leurs, Iwan J P de Esch, Chris de Graaf. J Med Chem 2014
165
100

Pralsetinib: First Approval.
Anthony Markham. Drugs 2020
31
100

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature.
Sara Baglivo, Vienna Ludovini, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila, Giulio Metro. Oncol Ther 2020
10
100

Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Ly Nguyen, Shanada Monestime. Am J Health Syst Pharm 2022
1
100


A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
Soo-Ryum Yang, Umut Aypar, Ezra Y Rosen, Douglas A Mata, Ryma Benayed, Kerry Mullaney, Gowtham Jayakumaran, Yanming Zhang, Denise Frosina, Alexander Drilon,[...]. Clin Cancer Res 2021
14
100

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fulvio Basolo, Maria Domenica Castellone, Rosa Marina Melillo, Alfredo Fusco, Massimo Santoro. J Clin Endocrinol Metab 2003
103
100

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020.
Xiaoxia Liang, Qian Yang, Pan Wu, Changliang He, Lizi Yin, Funeng Xu, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li,[...]. Bioorg Chem 2021
8
100

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Alexander Drilon, Siqing Fu, Manish R Patel, Marwan Fakih, Ding Wang, Anthony J Olszanski, Daniel Morgensztern, Stephen V Liu, Byoung Chul Cho, Lyudmila Bazhenova,[...]. Cancer Discov 2019
67
100

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
35
100

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
I Plaza-Menacho, A Morandi, D Robertson, S Pancholi, S Drury, M Dowsett, L-A Martin, C M Isacke. Oncogene 2010
96
100


The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
Tao Shen, Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H M Mooers, Jie Wu. NPJ Precis Oncol 2021
9
100

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
195
100

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
C Belli, F Penault-Llorca, M Ladanyi, N Normanno, J-Y Scoazec, L Lacroix, J S Reis-Filho, V Subbiah, J F Gainor, V Endris,[...]. Ann Oncol 2021
28
100

Therapeutic Advances in Oncology.
Jinsha Liu, Priyanka Pandya, Sepideh Afshar. Int J Mol Sci 2021
8
100

Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
Ellinor Andersson, Yvonne Arvidsson, Christina Swärd, Tobias Hofving, Bo Wängberg, Erik Kristiansson, Ola Nilsson. Mod Pathol 2016
23
100

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
89
100

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Rana Hatem, Dalila Labiod, Sophie Château-Joubert, Ludmilla de Plater, Rania El Botty, Sophie Vacher, Florian Bonin, Jean-Luc Servely, Véronique Dieras, Ivan Bièche,[...]. Int J Cancer 2016
27
100

RET kinase alterations in targeted cancer therapy.
Xuan Liu, Xueqing Hu, Tao Shen, Qi Li, Blaine H M Mooers, Jie Wu. Cancer Drug Resist 2020
1
100

Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
Pietro Locantore, Roberto Novizio, Andrea Corsello, Rosa Maria Paragliola, Alfredo Pontecorvi, Salvatore Maria Corsello. Expert Opin Drug Discov 2022
3
100

To Continue or Not to Continue? That Is the Question.
Marina Chiara Garassino, Benjamin Besse, Valter Torri. J Clin Oncol 2020
2
100

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Aparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, Le Huang, Shuang Liu, Kenneth Hess, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman,[...]. ESMO Open 2020
19
100

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan. Nat Rev Clin Oncol 2018
134
100

Advances in Targeting RET-Dependent Cancers.
Vivek Subbiah, Gilbert J Cote. Cancer Discov 2020
44
100


State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric-Bernstam. J Clin Oncol 2020
76
100

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Andrea Morandi, Lesley-Ann Martin, Qiong Gao, Sunil Pancholi, Alan Mackay, David Robertson, Marketa Zvelebil, Mitch Dowsett, Ivan Plaza-Menacho, Clare M Isacke. Cancer Res 2013
66
100

REToma: a cancer subtype with a shared driver oncogene.
Takashi Kohno, Junya Tabata, Takashi Nakaoku. Carcinogenesis 2020
21
100

Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.
Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C Roloff, Martin Schreiber, Neil Carragher, Kenneth K Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner,[...]. EMBO Mol Med 2013
54
100

Decade in review: a new era for RET-rearranged lung cancers.
Noura J Choudhury, Alexander Drilon. Transl Lung Cancer Res 2020
6
100

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
J J Lin, S V Liu, C E McCoach, V W Zhu, A C Tan, S Yoda, J Peterson, A Do, K Prutisto-Chang, I Dagogo-Jack,[...]. Ann Oncol 2020
58
100

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Ibiayi Dagogo-Jack, Sara E Stevens, Jessica J Lin, Rebecca Nagy, Lorin Ferris, Alice T Shaw, Justin F Gainor. J Thorac Oncol 2018
30
100

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
M Santoro, F Carlomagno, A Romano, D P Bottaro, N A Dathan, M Grieco, A Fusco, G Vecchio, B Matoskova, M H Kraus. Science 1995
703
100

The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
Anne Boulay, Madlaina Breuleux, Christine Stephan, Caroline Fux, Cathrin Brisken, Maryse Fiche, Markus Wartmann, Michael Stumm, Heidi A Lane, Nancy E Hynes. Cancer Res 2008
87
100

Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.
Nicholas F Lawrence, Marc R Hammond, Dennie T Frederick, Yuhua Su, Dora Dias-Santagata, April Deng, M Angelica Selim, Meera Mahalingam, Keith T Flaherty, Mai P Hoang. J Am Acad Dermatol 2016
16
100

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
Yong-Pyo Lee, Byeong-Ho Jeong, Yeonghee Eun, Cheol-In Kang, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park,[...]. Eur J Cancer 2021
1
100

A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.
Selma Esseghir, S Katrina Todd, Toby Hunt, Richard Poulsom, Ivan Plaza-Menacho, Jorge S Reis-Filho, Clare M Isacke. Cancer Res 2007
101
100

Functional RET G691S polymorphism in cutaneous malignant melanoma.
N Narita, A Tanemura, R Murali, R A Scolyer, S Huang, T Arigami, S Yanagita, K K Chong, J F Thompson, D L Morton,[...]. Oncogene 2009
54
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.